Semaglutide

What Is Semaglutide?

Semaglutide is a lab-made version of GLP-1, a hormone your gut releases after you eat. GLP-1 tells your brain you are full, slows your stomach from emptying, and helps your pancreas release insulin. The problem with natural GLP-1 is that it breaks down in about 90 seconds—far too fast to be useful as a medicine.

Novo Nordisk, the Danish pharmaceutical company that developed semaglutide, solved this by making three changes to the molecule:

1. A structural tweak that blocks breakdown. One amino acid swap prevents the enzyme that normally destroys GLP-1 from recognizing semaglutide. This single change extends its active life from 90 seconds to about 7 days.

2. A fatty acid anchor. A fat molecule attached to semaglutide lets it hitch a ride on albumin, a protein that circulates in the blood for weeks. This keeps semaglutide in the bloodstream much longer than the natural hormone.

3. An oral absorption helper (Rybelsus only). For the pill version, semaglutide is paired with a compound called SNAC that helps it cross the stomach lining. Only about 1% of the dose makes it into the blood this way—which is why the oral dose (7–14 mg daily) is much higher than the injectable dose (up to 2.4 mg weekly).

The result is a molecule that does what your body’s own GLP-1 does, but sticks around long enough to produce sustained effects on appetite, blood sugar, and body weight. You inject it once a week (Ozempic for diabetes, Wegovy for weight loss) or take a daily pill (Rybelsus). The injectable form is more potent milligram-for-milligram, which is why it remains the clinical standard.

Origins and Development

Semaglutide is the evolutionary successor to liraglutide, the first GLP-1 receptor agonist approved for chronic weight management (Saxenda, 2014). The development path began with foundational work by Jens Juul Holst and Jens Habener at the University of Copenhagen, who identified GLP-1 as a regulator of postprandial glucose and appetite in the 1980s and 1990s.

Novo Nordisk refined this insight by engineering longer-acting analogs. Liraglutide (half-life ~13 hours) required daily injection. Semaglutide's half-life of 7 days represented a 10-fold improvement, enabling once-weekly dosing—a major quality-of-life and adherence advantage. The clinical validation occurred through sequential large Phase III programs:

• SUSTAIN program (2015-2017) — Six trials in type 2 diabetes, establishing efficacy in glycemic control and CV risk reduction
• STEP program (2019-2021) — Five trials in obesity without diabetes, confirming ~15% weight loss across diverse populations
• SELECT trial (2023) — 17,604 participants with obesity/overweight and established CVD, proving 20% MACE reduction
• PIONEER program (2019-2020) — Oral formulation trials, establishing Rybelsus efficacy

Semaglutide received FDA approval for type 2 diabetes (Ozempic) in December 2017, for oral use (Rybelsus) in September 2019, and for chronic weight management (Wegovy) in June 2021. In 2024, the FDA approved a new indication for cardiovascular risk reduction based on SELECT data.

Mechanism of Action

Semaglutide's therapeutic effects arise from systemic GLP-1 receptor (GLP-1R) agonism across multiple tissues. The GLP-1R is expressed on pancreatic beta cells, gastric smooth muscle, neurons in the brain stem and hypothalamus, and endothelial cells throughout the cardiovascular system. Each site contributes distinct mechanisms:

Pancreatic Mechanism: Glucose-Dependent Insulin Secretion

GLP-1R activation on pancreatic beta cells increases intracellular cAMP, opening potassium channels and depolarizing the cell membrane. This triggers calcium influx and insulin granule exocytosis. Critically, this effect is glucose-dependent—insulin release only occurs when blood glucose is elevated. When glucose normalizes, the signal dissipates. This mechanism prevents hypoglycemia, a major advantage over insulin secretagogues.

Additionally, semaglutide suppresses glucagon secretion from pancreatic alpha cells in a glucose-dependent manner. When blood glucose is low, glucagon release is preserved, maintaining hepatic glucose output and preventing hypoglycemia.

Gastric Mechanism: Delayed Gastric Emptying

GLP-1R signaling in gastric smooth muscle slows the rate at which food moves from the stomach to the small intestine, extending the postprandial phase and blunting postprandial glucose spikes. This effect is evident within hours of injection and contributes to both glycemic control and early satiety. The delayed emptying is often perceived as nausea during dose escalation but diminishes with time.

Central Appetite Suppression

GLP-1 neurons originating in the nucleus tractus solitarius project to the hypothalamus and limbic system. GLP-1R activation in the paraventricular nucleus suppresses orexigenic neurons while activating anorexigenic neurons. The net effect is reduced hunger signaling and increased satiety. Beyond appetite, GLP-1R signaling in the mesolimbic reward circuit modulates dopamine release in response to food cues, dampening the hedonic drive to consume highly palatable foods.

Cardiovascular Mechanism

GLP-1R expression is present on vascular endothelial cells, cardiomyocytes, and immune cells. Semaglutide's CV benefit in SELECT arises from multiple mechanisms: improved glycemic control, weight loss-induced reductions in visceral adiposity, decreased systemic inflammation, improved endothelial function, modest reductions in blood pressure and heart rate, and direct cardioprotective signaling.

Approved Indications and Regulatory Milestones

Key Research Areas and Studies

STEP Program: Weight Loss in Obesity

The STEP program comprises five randomized controlled trials published between 2019-2021, collectively enrolling over 4,500 participants with obesity (BMI greater-than 30) without diabetes. Key trials include: STEP 1 (N=1,961, 68 weeks) showed ~15.3% weight loss vs. 2.6% placebo with 86% achieving ≥5% weight loss. STEP 3 (N=611, 56 weeks) combined semaglutide with lifestyle intervention, achieving ~17.5% weight loss (vs. 8% lifestyle alone). STEP 4 (N=902, 52 weeks treatment + 48 weeks off) showed weight regain of ~two-thirds within 1 year post-cessation. STEP 5 (N=304, 104 weeks) confirmed sustained ~15% weight loss at 2 years with continuous dosing.

SELECT: Cardiovascular Outcomes and the Paradigm Shift

SELECT (Semaglutide Effects on Cardiovascular Outcomes in People Living with Obesity) enrolled 17,604 participants with established cardiovascular disease and obesity or overweight, but no diabetes. The primary composite outcome was major adverse cardiovascular events (MACE: non-fatal MI, non-fatal stroke, cardiovascular death). Results: Semaglutide reduced MACE by 20% (HR 0.80, 95% CI 0.72-0.90). This was a landmark finding: no anti-obesity medication had ever reduced hard cardiovascular events in such a large population. Secondary outcomes included 41% reduction in non-fatal MI and 39% reduction in stroke.

SUSTAIN Program: Glycemic Control and CV Benefits in Type 2 Diabetes

The SUSTAIN program comprises six large Phase III trials in type 2 diabetes. SUSTAIN-1 through SUSTAIN-5 showed HbA1c reduction of 1.5-1.8% vs. placebo. SUSTAIN-6 (N=3,297, 2.4-year median follow-up) demonstrated semaglutide reduced MACE by 26% (HR 0.74, 95% CI 0.58-0.95), with three-point MACE reduction driven by 26% non-fatal MI reduction and 39% stroke reduction.

SURMOUNT-5: Head-to-Head Comparison with Tirzepatide

SURMOUNT-5 directly compares semaglutide (2.4 mg weekly) to tirzepatide (15 mg weekly), a newer GLP-1/GIP receptor agonist. In a 52-week non-inferiority trial of 711 participants, tirzepatide achieved ~22% weight loss vs. semaglutide's ~16%. This represents meaningful head-to-head superiority of tirzepatide, which has shifted clinical conversations about drug selection for pure weight-loss goals. However, semaglutide's longer track record and proven CV benefit remain compelling.

SEMALEAN: Muscle Mass and Body Composition

SEMALEAN is a post-hoc analysis of STEP trial participants evaluating changes in lean body mass during semaglutide therapy. The study tracked 341 participants over 68 weeks of treatment and subsequent withdrawal. Key findings: Lean mass declined approximately 3 kg (or ~25-30% of total weight loss) by month 7, then stabilized—no further loss occurred through month 12. Following drug withdrawal, approximately 50-70% of lean mass loss was recovered within 12 months. Protein intake (≥1.2-1.6 g/kg/day) plus concurrent resistance training substantially mitigate lean mass loss.

Common Claims versus Current Evidence

We currently don’t have any vetted partners for this compound. Check back soon.

The Human Evidence Landscape

Semaglutide's place in contemporary medicine didn't come from a single pivotal trial. It came from five overlapping Phase III programs that together enrolled more than 30,000 patients and defined, in sequence, the indications the drug now carries — and from a handful of trials still reading out that are either extending those indications or testing whether the molecule does something the earlier trials didn't anticipate.

The Trial Programs That Built the Label

The SUSTAIN program (10 trials in type 2 diabetes) established glycemic efficacy and the weekly-subcutaneous dosing schema. SUSTAIN-6, a cardiovascular outcomes trial in patients at elevated cardiovascular risk, showed a 26% reduction in the primary MACE endpoint over two years — the finding that first put GLP-1 agonists on cardiology's map.

The STEP program (STEP 1–8, obesity) carried the drug into its second blockbuster indication. STEP 1, the 68-week trial in adults with obesity but without diabetes, reported a mean 14.9% reduction in body weight on 2.4 mg weekly — a magnitude no non-surgical intervention had reached.

The PIONEER program validated the oral formulation (Rybelsus), including PIONEER 6's cardiovascular safety finding. SELECT (17,604 patients with established cardiovascular disease and overweight or obesity, no diabetes) was the pivot. Published in 2023, it showed a 20% reduction in MACE in a non-diabetic population — the basis for the cardiovascular-risk-reduction indication that expanded the payer rationale far beyond glycemic control.

FLOW (chronic kidney disease with type 2 diabetes) and ESSENCE (metabolic dysfunction-associated steatohepatitis, MASH) extended the evidence further, stopping early for efficacy in both cases.

Cardiovascular and Mortality Outcomes

The cardiovascular story is the strongest single pillar of the evidence base. SELECT's 20% MACE reduction in a non-diabetic population is the largest effect size for a non-statin agent in contemporary secondary prevention. Mortality data are more measured: all-cause mortality in SELECT trended favorably but did not cross the significance threshold on its own, though pooled analyses across SUSTAIN-6, PIONEER-6, and SELECT suggest the direction is consistent.

What's in the data: benefit in patients with established atherosclerotic cardiovascular disease. What isn't: primary prevention. Trials in lower-risk populations have not been completed, and clinicians should not extrapolate SELECT-scale benefit to patients without the cardiovascular risk profile SELECT enrolled.

Weight Loss, Body Composition, and Metabolic Health

STEP 1's 14.9% mean body weight reduction is the headline figure, and it has held up across replication. STEP 3 (with intensive behavioral therapy), STEP 4 (a withdrawal trial showing rapid weight regain after discontinuation), STEP 5 (two-year maintenance data), and STEP 8 (head-to-head against liraglutide, where semaglutide won) filled in the picture around the primary effect.

Body composition is the less-resolved question. DEXA subcohort analyses from STEP trials show that roughly 40% of weight loss comes from lean mass — a finding that has provoked legitimate clinical debate about whether the speed and magnitude of loss exceed what the body's adaptive machinery can handle gracefully. The lean-mass question is active. The efficacy question on total weight loss is not. STEP-HFpEF extended the evidence into heart failure with preserved ejection fraction, showing symptom improvement alongside weight reduction.

Renal, Hepatic, and Adolescent Evidence

FLOW (3,533 patients with type 2 diabetes and CKD) stopped early at interim analysis for efficacy — semaglutide reduced the primary composite of kidney failure, substantial loss of kidney function, and death from kidney or cardiovascular causes by 24%. It is the first GLP-1 outcomes trial powered specifically for renal endpoints.

ESSENCE (Phase III, MASH with liver fibrosis) similarly stopped early for efficacy, with both fibrosis improvement and MASH resolution meeting their endpoints. A MASH indication is expected to follow the full data publication.

STEP TEENS extended efficacy into adolescents (ages 12 to 17), with a 16.1% mean body weight reduction — a magnitude similar to the adult trials. This became the basis for the pediatric obesity indication.

Where Evidence Is Still Emerging

Two areas remain legitimately open.

Neurodegenerative disease. The EVOKE and EVOKE Plus trials are testing oral semaglutide in early Alzheimer's disease. Interim hints from observational data and rodent work have generated substantial interest; the Phase III readouts are expected in the next two years. Until they read out, Alzheimer's is a hypothesis under test, not an indication.

Addiction and reward pathways. Observational data and small trials have suggested reduced alcohol consumption, smoking reduction, and possibly reduced use of other substances during GLP-1 therapy. Controlled trials in alcohol use disorder are underway. The signal is consistent enough to take seriously but not yet established.

Long-term safety beyond five years. The oldest SELECT participants have now been on semaglutide for roughly four years. The REMS-captured adverse event surveillance remains the primary vehicle for monitoring rare outcomes — thyroid C-cell tumors (the boxed warning carried forward from rodent data), pancreatitis, and the debated gastroparesis reports. The 10-year picture is, by definition, incomplete.

Safety, Risks, and Limitations

Gastrointestinal Effects

The most common adverse effects are gastrointestinal. In STEP 1, nausea occurred in 25% of semaglutide recipients vs. 5% placebo, vomiting in 8% vs. 1%, and diarrhea in 18% vs. 7%. These effects are dose-dependent and most severe during dose escalation. Approximately 70% of participants report resolution or substantial improvement by 12 weeks with consistent dosing. Slower dose escalation (12-week titration vs. standard 4-week escalation) reduces symptom severity.

Pancreatitis Risk

Post-marketing case reports of acute pancreatitis raised concern. However, meta-analyses and STEP program data do not show increased pancreatitis incidence compared to placebo. Estimated background risk is ~20-50 cases per 100,000 person-years; semaglutide does not elevate this significantly. People with personal or family history of pancreatitis should avoid GLP-1 agonists.

Gallstone Disease

Rapid weight loss increases bile supersaturation and gallstone formation. STEP substudies showed a two- to threefold increase in cholelithiasis in semaglutide recipients (typically 1-2% incidence vs. 0.3% placebo). Most gallstones are asymptomatic. Symptomatic cholelithiasis occurs in <0.5% of users. Risk factors include female sex, age >40, rapid weight loss, and low soluble fiber intake. Prophylactic ursodeoxycholic acid may reduce incidence in high-risk individuals.

Thyroid C-Cell Effects

All GLP-1 agonists cause C-cell hyperplasia and medullary thyroid carcinoma (MTC) in rodents at doses multiples higher than therapeutic doses in humans. This triggered FDA black box warnings despite no confirmed human MTC cases in post-marketing surveillance spanning millions of patient-years. Semaglutide is contraindicated in people with personal or family history of MTC or MEN syndrome type 2.

Lean Body Mass Loss

Semaglutide therapy results in loss of approximately 3 kg lean body mass (25-30% of total weight loss) during the first 7 months, then stabilization. This is within the normal range for caloric deficit. Recovery of 50-70% of lean mass occurs after drug cessation. Lean mass loss can be substantially mitigated by: (1) protein intake >=1.2-1.6 g/kg/day, (2) concurrent resistance training 3-4 times weekly, and (3) adequate caloric deficit.

Rebound Weight Gain

STEP 4 withdrawal data show that approximately two-thirds of weight loss is regained within 12 months after semaglutide cessation, though the rate of regain is slower than initial loss. This rebound reflects normalization of appetite-suppressing effects. It does not indicate drug failure but rather the expected physiologic response to removal of an appetite-suppressing stimulus.

Anti-Doping Status

Semaglutide is not prohibited by the World Anti-Doping Agency (WADA). GLP-1 receptor agonists were not included on the WADA Prohibited List as of 2024 and remain classified as non-prohibited medications. However, GLP-1 agonists are on the 2026 WADA Monitoring Program—a designation meaning they are under active surveillance for potential future prohibition if evidence of performance-enhancing effects emerges.

Competitive athletes can legally use semaglutide with a valid prescription for an approved indication (type 2 diabetes, obesity, cardiovascular risk reduction) without violating anti-doping rules. However, off-label use solely for weight loss in athletes without a medical indication may raise scrutiny.

Legal and Regulatory Status

Semaglutide is a prescription medication approved by the FDA for three indications: type 2 diabetes mellitus (Ozempic), chronic weight management (Wegovy), and cardiovascular risk reduction. Obtaining semaglutide without a valid prescription is illegal in the United States and most other jurisdictions.

Compounded Semaglutide: Quality Concerns

Compounded semaglutide became available following perceived shortages (2021-2022). Compounding pharmacies can legally prepare semaglutide under the FDA's 503A exemption if they lack an FDA-approved equivalent in supply. However, large-scale models occupy a regulatory gray zone. Quality issues have emerged: FDA investigations (2023-2024) identified compounded semaglutide batches with subpotency, bacterial contamination, and absence of identity testing. The agency issued multiple enforcement actions. Bioequivalence of compounded to branded semaglutide is not established.

Patent and Biosimilar Landscape

Novo Nordisk's semaglutide patent portfolio expires in 2026-2031 (depending on jurisdiction). Generic manufacturers are preparing abbreviated new drug application (ANDA) submissions for FDA approval, expected to launch in late 2026 to early 2027. Patent expiry and competitive launches will likely drive price reductions, improving accessibility.

Dosing: What's Approved vs. What's Practiced

Published FDA-approved dosing regimens vary by indication and route:

Dose escalation is standardized to minimize gastrointestinal tolerability. For Wegovy (obesity), the escalation schedule is 0.25 mg at weeks 0-4, 0.5 mg at weeks 4-8, 1.0 mg at weeks 8-12, 1.7 mg at weeks 12-16, and 2.4 mg at weeks 16+. Accelerating escalation increases nausea risk; slowing escalation improves tolerability at the cost of delayed efficacy.

Off-Label and Community Use

Semaglutide is a prescription medication—not a research peptide available through gray-market vendors. “Community protocols” in this context refers to off-label prescribing patterns documented by clinicians and patients, not underground self-experimentation.

Common off-label uses include:

Preparation and Storage

FDA-Approved Pens (Ozempic, Wegovy)

Semaglutide pens are pre-filled, single-use or multi-use delivery devices manufactured by Novo Nordisk. No reconstitution is required. Each pen is ready to inject immediately upon removal from packaging.

Storage: Refrigerated vs. Room Temperature

Before first use: Pens must be stored in a refrigerator at 2-8 degrees Celsius (36-46 degrees Fahrenheit). Do not freeze. If frozen, discard the pen.

After first use: Opened pens may be stored at room temperature up to 30 degrees Celsius (86 degrees Fahrenheit) for up to 56 days. Once 56 days have elapsed since first use, the pen must be discarded regardless of remaining drug volume.

Needle use: Each injection should use a new needle. Needles should be discarded in a sharps container after each use.

Compounded Semaglutide Storage

Compounded semaglutide typically arrives as a lyophilized powder in vials that requires reconstitution with bacteriostatic water for injection (BWFI). After reconstitution, it should be stored refrigerated at 2-8 degrees Celsius and is typically stable for 30-60 days depending on the pharmacy's stability data. If the vial shows discoloration, cloudiness, or particle formation, discard it.

Further Reading: See our Complete Storage Guide and Injection Technique Guide for detailed instructions.

Combination Stacks

Semaglutide is a prescription medication requiring physician oversight. Combination use must be discussed with and approved by the prescribing provider. The following combinations have evidence or clinical rationale:

Semaglutide + Resistance Training + High Protein (Evidence-Based)

Rationale: SEMALEAN data show that lean mass loss can be substantially mitigated by concurrent resistance training and protein intake >=1.2-1.6 g/kg/day. This combination is lifestyle-pharmacotherapy synergy. Practical protocol: Resistance training 3-4 days weekly plus protein intake 1.6-2.0 g/kg/day plus caloric deficit of 500-750 kcal/day produces robust weight loss while preserving muscle mass.

Semaglutide + Metformin (Standard Diabetic Practice)

Rationale: In type 2 diabetes management, semaglutide is commonly combined with metformin. Metformin reduces hepatic glucose production, semaglutide enhances insulin secretion and reduces appetite. Clinical trials show additive HbA1c reduction. Standard metformin dose (500-2,000 mg daily) plus semaglutide standard escalation. No dose adjustments required.

Semaglutide + SGLT2 Inhibitors (Complementary)

Rationale: SGLT2 inhibitors work via distinct mechanism: they increase urinary glucose excretion and improve renal hemodynamics. Combined use with semaglutide provides complementary glycemic control and independent cardiovascular and renal protective effects. This combination is increasingly standard in clinical practice for T2D with CVD. Multiple RCTs show additive HbA1c reduction when GLP-1 agonists and SGLT2i are combined.

Semaglutide + Tirzepatide (NOT Recommended)

Rationale for avoiding: Both are GLP-1 agonists (tirzepatide also activates GIP). Combining them provides redundant signaling without mechanistic complementarity. No clinical trial data support dual GLP-1/GIP agonism, and such combinations expose users to additive GI side effects without additional efficacy. Sequential use (switching from one to the other) is a better strategy.

Related Compounds: How Semaglutide Compares

Semaglutide is one of several GLP-1 receptor agonists and newer dual/triple agonists in clinical use. The comparison table below shows how semaglutide stacks up against other compounds in Cluster A (Weight Loss & Metabolic):

Key comparisons:

Semaglutide vs. Tirzepatide: Tirzepatide's dual GLP-1/GIP agonism provides superior weight loss (~22% vs. 15%) but semaglutide's longer safety track record and proven CV benefit (SELECT) in a large population remain compelling. Tirzepatide has not yet reported CV outcomes in large obesity trial; SUMMIT trial is ongoing.

Semaglutide vs. Retatrutide: Retatrutide (GLP-1/GIP/glucagon triple agonist) achieves ~24% weight loss in Phase 2 data and is advancing through Phase 3. It represents the next evolutionary step but lacks published CV outcome data that semaglutide possesses. Retatrutide may become the standard choice for pure weight-loss goals once CV data mature.

Semaglutide vs. Liraglutide: Liraglutide was the first GLP-1 agonist for obesity (Saxenda, 2014) but achieves only ~8% weight loss with daily injections. Semaglutide's longer half-life (weekly dosing) and superior efficacy (15% weight loss) make it the preferred GLP-1 choice. Liraglutide remains in use primarily for T2D (Victoza).

For a comprehensive comparison, see our Cluster A Weight Loss & Metabolic Hub.

Frequently Asked Questions

Summary and Key Takeaways

• Semaglutide is a GLP-1 receptor agonist that produces ~15% body weight loss and 20% cardiovascular event reduction in people with established CVD. It is the most extensively studied obesity medication in history (STEP, SELECT, SUSTAIN programs with N>20,000).
• Weekly injection dosing (0.25-2.4 mg SC) or daily oral tablets (7-14 mg) provide similar pharmacodynamic efficacy. Weekly injection is the clinical standard.
• Lean body mass loss (~25-30% of total weight loss) stabilizes after 7 months and is substantially mitigated by high protein intake (>=1.2-1.6 g/kg/day) and concurrent resistance training (SEMALEAN data).
• Cardiovascular benefit is real and proven. SELECT demonstrated 20% MACE reduction in non-diabetic obesity with established CVD. This remains unique to semaglutide among anti-obesity drugs.
• Gastrointestinal side effects (nausea, diarrhea) are common early but resolve in ~70% of users by week 12. Slower dose escalation minimizes severity.
• Tirzepatide achieves ~22% weight loss (superior to semaglutide's 15%), but semaglutide's longer clinical evidence base and proven CV benefit remain compelling for initial choice in many populations.
• Weight regain (~two-thirds of loss) occurs within 12 months of discontinuation. This is physiologic normalization, not drug failure. Continuous dosing is required for sustained weight loss.
• Compounded semaglutide carries quality risks (subpotency, contamination). FDA-approved formulations carry regulatory guarantees that compounded versions do not.

Verdict Recapitulation

Semaglutide is the most evidence-supported anti-obesity medication available today. Phase III trials exceed 20,000 participants across multiple indications. The SELECT trial’s demonstration of cardiovascular mortality benefit—a first for the drug class—places semaglutide in a unique position as both a weight-loss agent and a proven cardiovascular therapeutic. Newer compounds (tirzepatide, retatrutide) may surpass semaglutide’s weight-loss efficacy, but until CV outcome data mature for these agents, semaglutide remains the evidence-based first choice for people with cardiovascular disease and obesity. For pure weight-loss goals without established CVD, tirzepatide’s superior efficacy may justify switching, but semaglutide’s long track record and known safety profile remain compelling.

Where to Source Semaglutide

Further Reading and Resources

If you want to go deeper on semaglutide, the evidence landscape for weight loss and metabolic peptides, or the methodology behind how we evaluate this research, these are the places worth your time.

On Peptidings

• Tirzepatide — GLP-1/GIP dual agonist with superior weight loss efficacy
• Retatrutide — Triple GLP-1/GIP/GCG agonist in Phase 3 trials
• Liraglutide — Earlier-generation GLP-1 agonist
• CagriSema — GLP-1 + amylin dual agonist (Phase 3)
• Weight Loss & Metabolic Hub — All compounds in this category
• About Peptidings — Our editorial methodology and evidence framework
• Evidence Framework — How we evaluate and tier the research

External Resources

• PubMed — Biomedical Research Database — Search for “semaglutide” or related terms.
• ClinicalTrials.gov — Check for registered or ongoing trials.

Selected References and Key Studies

All citations include PubMed links and direct access to published data:

1. Wilding JPH, et al. Weight loss and cardiometabolic outcomes with semaglutide. N Engl J Med. 2021;384(11):989-1002. PubMed
2. Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232. PubMed
3. Marso SP, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834-1844. PubMed
4. Rubino DM, et al. Effect of continued semaglutide vs. placebo on weight loss maintenance in adults with obesity. JAMA. 2022;327(2):138-150. PubMed
5. Novo Nordisk. Semaglutide prescribing information. 2024.
6. Davies M, et al. Semaglutide in type 2 diabetes (STEP 2). Lancet. 2021;397(10291):1971-1984. PubMed
7. Rubino D, et al. Withdrawal and weight regain in the STEP 4 trial. JAMA. 2021;325(14):1414-1425. PubMed
8. Garvey WT, et al. Two-year efficacy and safety of semaglutide (STEP 5). Nat Med. 2022;28:2083-2091. PubMed
9. Husain M, et al. Oral semaglutide and cardiovascular outcomes (PIONEER 6). N Engl J Med. 2019;381(9):841-851. PubMed
10. Lundgren JR, et al. Muscle mass and body composition with semaglutide: the SEMALEAN randomized trial. Obesity. 2025. PubMed
11. Aronne LJ, et al. Tirzepatide versus semaglutide for weight loss: the SURMOUNT-5 trial. N Engl J Med. 2025. PubMed
12. Lingvay I, et al. Semaglutide for cardiometabolic risk reduction in overweight or obese adults: SELECT trial secondary endpoints. Lancet. 2024;403(10437):1635-1648. PubMed
13. Aroda VR, et al. Efficacy and safety of oral semaglutide (PIONEER 1). Diabetes Care. 2019;42(9):1724-1732. PubMed
14. Wadden TA, et al. Semaglutide and lifestyle intervention (STEP 3). JAMA. 2021;325(14):1403-1413. PubMed

About the Author

Lawrence Winnerman

Founder of Peptidings.com. Former big tech product manager. Independent peptide researcher focused on translating clinical evidence into accessible science.